---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-26-000011"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:51:37.641482+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B

## Summary
- Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.
- Full year 2025 revenue $812.0M (+97% YoY); net loss narrowed to $68.1M from $281.9M; Adj. EBITDA $137.7M.
- Gross margin improved to 75% in Q4 (from 54%) and 66% for FY (from 43%).
- FY26 revenue guidance $1.0-1.02B (23-26% growth); molecular profiling rev growth ~21-22%.
- Interim readout of Achieve 1 study for Caris Detect MCED test completed; launch expected H1 2026.

## SEC filing metadata
- accession: 0002019410-26-000011
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000011/0002019410-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000011/cai-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-26-000011
- JSON: https://secwatch.observer/filing/0002019410-26-000011.json
- Plain text: https://secwatch.observer/filing/0002019410-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.